Abstract
The Lescol Intervention Prevention Study (LIPS) was the first randomized trial to show a significant reduction in the risk of cardiac events in patients started on fluvastatin immediately after a successful percutaneous coronary intervention. The benefit was independent of baseline cholesterol levels. The results suggest that all patients should be discharged on lipid-lowering therapy after a percutaneous coronary intervention. Currently, this is seldom done.
| Original language | English |
|---|---|
| Pages (from-to) | 561-566 |
| Number of pages | 6 |
| Journal | Cleveland Clinic Journal of Medicine |
| Volume | 70 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2003 |
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Start all patients on statins early after PCI'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver